JP6170435B2 - 改変ノッチンペプチドを含む融合タンパク質及びその使用 - Google Patents

改変ノッチンペプチドを含む融合タンパク質及びその使用 Download PDF

Info

Publication number
JP6170435B2
JP6170435B2 JP2013537908A JP2013537908A JP6170435B2 JP 6170435 B2 JP6170435 B2 JP 6170435B2 JP 2013537908 A JP2013537908 A JP 2013537908A JP 2013537908 A JP2013537908 A JP 2013537908A JP 6170435 B2 JP6170435 B2 JP 6170435B2
Authority
JP
Japan
Prior art keywords
binding
receptor
axl
integrin
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504270A (ja
JP2014504270A5 (enExample
Inventor
アール コクラン ジェニファー
アール コクラン ジェニファー
エス ジョーンズ ダグラス
エス ジョーンズ ダグラス
エス カリオリス ミハリス
エス カリオリス ミハリス
ピンーチュアン ツァイ
ピンーチュアン ツァイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2014504270A publication Critical patent/JP2014504270A/ja
Publication of JP2014504270A5 publication Critical patent/JP2014504270A5/ja
Application granted granted Critical
Publication of JP6170435B2 publication Critical patent/JP6170435B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013537908A 2010-11-08 2011-11-07 改変ノッチンペプチドを含む融合タンパク質及びその使用 Expired - Fee Related JP6170435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41135010P 2010-11-08 2010-11-08
US61/411,350 2010-11-08
PCT/US2011/059599 WO2012064658A1 (en) 2010-11-08 2011-11-07 Fusion proteins comprising an engineered knottin peptide and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017079525A Division JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2014504270A JP2014504270A (ja) 2014-02-20
JP2014504270A5 JP2014504270A5 (enExample) 2014-12-25
JP6170435B2 true JP6170435B2 (ja) 2017-07-26

Family

ID=46051256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537908A Expired - Fee Related JP6170435B2 (ja) 2010-11-08 2011-11-07 改変ノッチンペプチドを含む融合タンパク質及びその使用
JP2017079525A Expired - Fee Related JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017079525A Expired - Fee Related JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Country Status (7)

Country Link
US (3) US10844106B2 (enExample)
EP (2) EP3604549A1 (enExample)
JP (2) JP6170435B2 (enExample)
AU (3) AU2011326164B2 (enExample)
CA (1) CA2817197C (enExample)
DK (1) DK2638173T3 (enExample)
WO (1) WO2012064658A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
DK2638173T3 (da) 2010-11-08 2019-09-30 Univ Leland Stanford Junior Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
WO2013078250A2 (en) 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
CA2913127A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Methods for screening
PT3326622T (pt) * 2012-12-14 2021-04-07 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016025642A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
CN107847554A (zh) * 2015-06-26 2018-03-27 弗莱德哈钦森癌症研究中心 治疗性肽及其使用方法
WO2017044894A2 (en) 2015-09-09 2017-03-16 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017118761A1 (en) * 2016-01-08 2017-07-13 Iontas Ltd Binding members with altered diversity scaffold domains
WO2017139570A1 (en) * 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
WO2017160879A1 (en) 2016-03-15 2017-09-21 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
WO2018044234A1 (en) * 2016-08-31 2018-03-08 Nanyang Technological University Cysteine-rich polypeptides and conjugates and methods of using the same
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
EP3571215A4 (en) 2017-01-18 2020-12-30 Fred Hutchinson Cancer Research Center PEPTIDIC COMPOSITIONS AND THEIR METHODS OF USE TO DISTURB TEAD INTERACTIONS
AU2018236465A1 (en) 2017-03-16 2019-08-22 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
US11331393B2 (en) 2017-06-15 2022-05-17 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
AU2018307752A1 (en) 2017-07-24 2020-03-12 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
WO2020205836A1 (en) * 2019-04-02 2020-10-08 Eli Lilly And Company Methods of selecting and detecting binding peptides
CA3135676A1 (en) * 2019-04-29 2020-11-05 The Board Of Trustees Of The Leland Stanford Junior University Methods of ocular treatment using an engineered dimeric fragment of hepatocyte growth factor
US20220211861A1 (en) * 2019-05-22 2022-07-07 The Board of Trustees of the Leland Staford Junior University Drug conjugates and methods of using same
US20220257785A1 (en) * 2019-09-30 2022-08-18 The Board Of Trustees Of The Leland Stanford Junior University Knottin-immunostimulant conjugates and related compositions and methods
WO2022026906A2 (en) * 2020-07-30 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University Lysosomal targeting molecules comprising knottin peptides and related compositions and methods
MX2020012914A (es) * 2020-11-27 2022-05-30 Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese Proteina andamio para la generacion de proteinas quimericas de union a antigeno.
WO2025255078A1 (en) * 2024-06-04 2025-12-11 The Children's Hospital Of Philadelphia Pan-solid tumor targeting cell therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6303749B1 (en) * 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
EP1358211A2 (en) 2001-01-31 2003-11-05 Mount Sinai Hospital Methods for regulating the kinase domain of ephb2
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US7674881B2 (en) 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
WO2009005813A1 (en) 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP2195028A2 (en) * 2007-09-18 2010-06-16 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2010048588A2 (en) 2008-10-23 2010-04-29 Massachusetts Institute Of Technology Directed engagement of activating fc receptors
US8329826B2 (en) 2008-11-06 2012-12-11 The Board Of Trustees Of The Leland Stanford Junior University Surface modification of interpenetrating polymer networks
US8778888B2 (en) 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
PT3241840T (pt) 2010-01-22 2022-10-13 Univ Leland Stanford Junior Inibição da sinalização de axl em terapêutica anti-metastática
DK2638173T3 (da) 2010-11-08 2019-09-30 Univ Leland Stanford Junior Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
US10350266B2 (en) * 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein

Also Published As

Publication number Publication date
DK2638173T3 (da) 2019-09-30
AU2016210712B2 (en) 2017-10-26
JP2017160222A (ja) 2017-09-14
AU2018200587A1 (en) 2018-02-15
WO2012064658A1 (en) 2012-05-18
CA2817197C (en) 2020-08-04
AU2018200587B2 (en) 2019-12-12
US11498952B2 (en) 2022-11-15
EP2638173A4 (en) 2014-03-26
US20140073518A1 (en) 2014-03-13
US20210206824A1 (en) 2021-07-08
AU2011326164B2 (en) 2016-05-05
CA2817197A1 (en) 2012-05-18
AU2011326164A1 (en) 2013-05-30
EP3604549A1 (en) 2020-02-05
US10844106B2 (en) 2020-11-24
EP2638173B1 (en) 2019-06-19
US12240882B2 (en) 2025-03-04
JP2014504270A (ja) 2014-02-20
AU2016210712A1 (en) 2016-09-08
US20230227523A1 (en) 2023-07-20
JP6535361B2 (ja) 2019-06-26
EP2638173A1 (en) 2013-09-18

Similar Documents

Publication Publication Date Title
US12240882B2 (en) Fusion proteins comprising an engineered knottin peptide and uses thereof
JP6783797B2 (ja) 抗がん融合ポリペプチド
JP6041799B2 (ja) Ｔｒａｉｌｒ２特異的多量体足場
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
KR101151805B1 (ko) 바이포달 펩타이드 바인더
TR201906295T4 (tr) IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri.
US20080160574A1 (en) Chimeric coiled coil molecules
US20100093624A1 (en) Peptide therapeutics that bind vegf and methods of use thereof
TW201107471A (en) Polypeptides selective for αvβ3 integrin conjugated with a variant of human serum albumin (HSA) and pharmaceutical uses thereof
JP6717725B2 (ja) 遺伝子操作した成長因子変異体
US12415868B1 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
KR102717638B1 (ko) 뉴레귤린-4 화합물 및 사용 방법
KR102150419B1 (ko) Pd-l1에 결합하는 펩타이드 및 이의 용도
AU2011347327A1 (en) uPAR-antagonists and uses thereof
KR20120125455A (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
KR101263424B1 (ko) 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
WO2018109771A1 (en) Fusion proteins for treatment of cancer
Baber Characterising the molecular interaction between CLEC14A and Multimerin 2
JP2026514918A (ja) Ｋｒａｓ突然変異を識別する高親和性ｔ細胞受容体及びその応用
CN115991780A (zh) 一种抗人血小板胶原蛋白受体gp-vi抗体或其抗原结合片段及其应用
HK40101426A (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK40064429B (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK1087418B (en) Fusion polypeptides, and use thereof in antivascular tumor therapy
HK1087418A1 (en) Fusion polypeptides, and use thereof in antivascular tumor therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170413

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170630

R150 Certificate of patent or registration of utility model

Ref document number: 6170435

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees